-
Je něco špatně v tomto záznamu ?
Analysis of prognostic significance of merkel cell polyomavirus in chronic lymphocytic leukemia
J. Trizuljak, J. Srovnal, K. Plevová, Y. Brychtová, L. Semerád, D. Bakešová, E. Létalová, A. Benedíková, J. Mayer, M. Hajdúch, Š. Pospíšilová, M. Doubek,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NT13493
MZ0
CEP - Centrální evidence projektů
- MeSH
- chronická lymfatická leukemie diagnóza virologie MeSH
- elektroforéza v polyakrylamidovém gelu MeSH
- infekce onkogenními viry diagnóza virologie MeSH
- kvantitativní polymerázová řetězová reakce MeSH
- lidé středního věku MeSH
- lidé MeSH
- Merkelův polyomavirus patogenita MeSH
- mutace MeSH
- polyomavirové infekce diagnóza virologie MeSH
- prevalence MeSH
- prognóza MeSH
- těžké řetězce imunoglobulinů genetika MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. PATIENTS AND METHODS: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. RESULTS: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. CONCLUSION: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.
Central European Institute of Technology Masaryk University Brno Czech Republic
Department of Internal Medicine Hematology and Oncology University Hospital Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16010472
- 003
- CZ-PrNML
- 005
- 20240717105559.0
- 007
- ta
- 008
- 160408s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clml.2015.02.003 $2 doi
- 024 7_
- $a 10.1016/j.clml.2015.02.003 $2 doi
- 035 __
- $a (PubMed)25758600
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Trizuljak, Jakub $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0230707
- 245 10
- $a Analysis of prognostic significance of merkel cell polyomavirus in chronic lymphocytic leukemia / $c J. Trizuljak, J. Srovnal, K. Plevová, Y. Brychtová, L. Semerád, D. Bakešová, E. Létalová, A. Benedíková, J. Mayer, M. Hajdúch, Š. Pospíšilová, M. Doubek,
- 520 9_
- $a BACKGROUND: Merkel cell polyomavirus (MCPyV), a ubiquitous DNA tumor virus, has been found to be associated with Merkel cell carcinoma and chronic lymphocytic leukemia (CLL). Previous studies have reported conflicting results on the frequency and potential pathogenetic role of MCPyV in CLL. The aim of this study was to evaluate MCPyV's association with CLL and its prognostic significance. PATIENTS AND METHODS: Between 2006 and 2013, DNA samples obtained from CLL patients (n = 119) before treatment were tested for MCPyV using quantitative real-time polymerase chain reaction analysis and verified by gel electrophoresis. Only samples testing positive by both methods were considered valid. RESULTS: We found that 13 (11%) of 119 CLL cases were positive for MCPyV. Between the groups of MCPyV-positive and -negative patients, there was no significant difference in the sex, age, cytogenetics, presence of p53 defect, or immunoglobulin heavy chain (IGHV) mutational status. In the subset of MCPyV-negative patients, advanced Rai stage (III to IV) was found more frequently, and therapy was initiated more often. There was no difference in overall response rate, median progression-free survival, and overall survival between both groups. We did not observe any new positivity after treatment in initially MCPyV-negative patients. CONCLUSION: This study provides the first analysis of the prognostic role of MCPyV in CLL. MCPyV occurrence seems to be a relatively rare event during the course of CLL. MCPyV is also unlikely to influence the outcome of CLL patients.
- 650 _2
- $a elektroforéza v polyakrylamidovém gelu $7 D004591
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a těžké řetězce imunoglobulinů $x genetika $7 D007143
- 650 _2
- $a chronická lymfatická leukemie $x diagnóza $x virologie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a Merkelův polyomavirus $x patogenita $7 D059965
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a polyomavirové infekce $x diagnóza $x virologie $7 D027601
- 650 _2
- $a prevalence $7 D015995
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a kvantitativní polymerázová řetězová reakce $7 D060888
- 650 _2
- $a infekce onkogenními viry $x diagnóza $x virologie $7 D014412
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Srovnal, Josef $u Institute of Molecular and Translational Medicine, Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University, and Faculty Hospital Olomouc, Czech Republic. $7 xx0091239
- 700 1_
- $a Plevová, Karla $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $7 xx0158852
- 700 1_
- $a Brychtová, Yvona $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0105542
- 700 1_
- $a Semerád, Lukáš $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0233574
- 700 1_
- $a Bakešová, Denisa $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic. $7 xx0320064
- 700 1_
- $a Létalová, Eva $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic.
- 700 1_
- $a Benedíková, Andrea $u Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $7 xx0169440
- 700 1_
- $a Mayer, Jiří, $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $d 1960- $7 nlk20000083651
- 700 1_
- $a Hajdúch, Marián, $u Institute of Molecular and Translational Medicine, Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University, and Faculty Hospital Olomouc, Czech Republic. $d 1969- $7 xx0050218
- 700 1_
- $a Pospíšilová, Šárka, $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. $d 1969- $7 xx0101843
- 700 1_
- $a Doubek, Michael, $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Czech Republic; Central European Institute of Technology (CEITEC), Masaryk University Brno, Czech Republic. Electronic address: mdoubek@fnbrno.cz. $d 1972- $7 mzk2004217554
- 773 0_
- $w MED00180199 $t Clinical lymphoma, myeloma & leukemia $x 2152-2669 $g Roč. 15, č. 7 (2015), s. 439-442
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25758600 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20240717105554 $b ABA008
- 999 __
- $a ok $b bmc $g 1113901 $s 934840
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 15 $c 7 $d 439-442 $e 20150211 $i 2152-2669 $m Clinical lymphoma, myeloma & leukemia $n Clin Lymphoma Myeloma Leuk $x MED00180199
- GRA __
- $a NT13493 $p MZ0
- LZP __
- $a Pubmed-20160408